You are here

Article info

Article menu

Download PDFPDF

XML
Immune Checkpoint Series
Tim-3 finds its place in the cancer immunotherapy landscape

Authors

  • Nandini Acharya Department of Neurology, Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Catherine Sabatos-Peyton Exploratory Immuno-oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Ana Carrizosa Anderson Department of Neurology, Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles

Citation

Acharya N, Sabatos-Peyton C, Anderson AC
Tim-3 finds its place in the cancer immunotherapy landscape
Journal for ImmunoTherapy of Cancer 2020;8:e000911. doi: 10.1136/jitc-2020-000911
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.